-
Americas
-
Asia & Oceania
-
A-I
J-Z
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Regions
-
Americas
-
Asia & Oceania
-
Europe
-
Middle East & Africa
-
Americas
-
Asia & Oceania
-
Europe
Europe
- Adriatic
- Belgium
- Bulgaria
- Czech Republic
- Deutschland
- España
- France
- Greece
- Hungary
- Ireland
- Israel
- Italia
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
WHO WE HELP
-
Pharmaceutical Manufacturers
-
Emerging Biopharma
-
MedTech
-
Financial Institutions
-
Government and Public Health
-
Health Plans
-
Hospital and Health Systems
-
Insurers and Risk
-
Medical Specialty and Patient Advocacy
Pharmaceutical Manufacturers
Harness unparalleled healthcare data, advanced analytics, and cutting-edge technologies with our expertise to accelerate the development and commercialization of innovative medicines, enhancing patient lives.
Discover MorePharmaceutical Manufacturers
Emerging Biopharma (Global page)
Boost your innovation with IQVIA's expert team. Our comprehensive solutions integrate top-tier insights, technology, and expertise to maximize your asset's success in a competitive landscape.
Discover InnovationsMedTech
Navigating MedTech's unique landscape: U.S. decision-making now rests with GPOs, IDNs, and payers, who demand solid value proof through rigorous outcomes analyses and pricing scrutiny.
Explore MedTechMedTech
Financial Institutions
Invest in healthcare with confidence. Stay ahead of pharma and medical device trends using real-time, high-quality data. Access market insights, historical sales, prescription trends, and emerging product information for informed, risk-reduced decisions.
Access InsightsGovernment and Public Health
Unlock deeper health insights with unmatched data and innovative technology to enhance decision-making for your essential government programs.
Unlock InnovationsGovernment and Public Health
Health Plans
Accelerate digital innovation with our data-driven expertise in data science and healthcare, optimizing business processes for smarter decisions.
Navigate Health PlansHospital and Health Systems
Leverage digital innovation to cut costs, boost efficiency, and elevate patient engagement, all while enhancing quality and health outcomes.
Streamline DecisionsHospital and Health Systems
Insurers and Risk
Enhance your ability to evaluate and forecast population risk swiftly and accurately by integrating unmatched data, expertise, and technology.
Uncover More
Medical Specialty and Patient Advocacy
Transform into a data-driven organization that enhances your specialty and showcases value to your members through digital transformation.
Explore NowU.S. PROGRESS POINT
A curation of IQVIA's best thinking on topics and trends driving change, disruption, and progress in the United States healthcare market.
LEARN MOREBLOGS, WHITE PAPERS & CASE STUDIES
Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTS
PODCASTS
"Discover the future through our enlightening podcasts available in the United States.
EXPLORE PODCASTS
Blog
Trends to Watch through 2023: Affordability economics
Mar 21, 2022
As we launch into 2022, it’s time for our stakeholders to look ahead and begin making and adjusting their yearly goals. It will be important to explore what trends in pharma are developing and how they may impact those working in the industry. In this blog series, we will explore the top seven trends we see emerging in 2022 and 2023, and how our customers should respond.
The entire industry is facing compressing economics. Patients, payers, pharmacies, policymakers, providers, health institutions, employers, and more are being challenged to address shifting healthcare economics and growing liabilities. For manufacturers, this has resulted in margin pressure and growing uncertainty on the future. One of the drivers of public discourse is the perception of drug costs in the U.S. as compared to the rest of the world.
Affordability economics — perceptions and reality
Drug costs contribute 14% to the overall cost of healthcare in the U.S. When this is examined against ten other developed countries, the cost of drugs in the U.S. system is comparable as a percentage of overall costs. The vast majority of the total healthcare spending relates to costs in other parts of the healthcare system, including hospital services, medical technology, infrastructure, supply chains, and provider reimbursement and salaries (figure 1).
This is not to say that pricing and healthcare reform is not needed. Rather, the facts of what the U.S. spends on drug costs is perceived to be more than other developed countries. While that may be true for raw dollars, it is important to contextualize what that spend represents as a part of the whole.
Additionally, many quickly turn to list prices because they are more readily observed while ignoring that net drug pricing has been at or below the rate of inflation for over five years. Making these facts transparent to key stakeholders will be an important effort in closing the significant gap between perceptions and reality.
Navigating the evolving market access ecosystem
All the efforts by policymakers, payers, PBMs, pharmacy chains, and healthcare systems – whether that be copay accumulators, 340B, value-based care arrangements, etc., – are part of a rapidly evolving market access ecosystem that generates growing margin pressures and complexity for manufacturers. For the patient, they are faced with an increasingly complex journey as they continue to get caught in the middle of trying to navigate an opaque system.
Understanding the drivers and implications of this evolving ecosystem is critical for pharma companies as they navigate these challenges.
An array of strategies and tactics are required for manufacturers:
- Enhance capabilities to address operational pressures, such as identifying duplicate discounts, distribution concentrations, copay program design, and preventable revenue leakage.
- Enrich insights through data and advanced analytics that improve net pricing transparency.
- Ensure compliance with and become codified. Model how shifting liabilities impact demand and margin.
- Help more patients gain access to treatments through manufacturer assistance and focus on improving health equity so that more patients can gain the full value of treatment.
- Improve forecasting and strategic planning to be proactive in assessing the impact of changes in the ecosystem and determine responses.
References
1 IQVIA Institute for Human Data Science, Drug Expenditure Dynamics. 1995-2020: Understanding Medicine Spending in Context, October 2021
Top Issues for Pharma to Watch in 2022 and 2023
Coming out of the global COVID-19 pandemic, the future holds both opportunity and increased complexity for the pharmaceutical industry. There are many important issues for pharma to watch in the near future as economic factors will continue to put pressure on revenue and margins. Seven important issues for pharma to watch in 2022 and 2023 that focus on policy, payer, and patients are explored during this webinar.